EFFECT OF ADJUVANT CHEMO FOR EARLY BREAST CA ON BRAIN IMAGING AMP; COGNITION

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 化疗相关的认知功能障碍，即所谓的“化疗脑”，是一种广泛报道但定义不明确的化疗并发症。尽管人们对这种潜在的毒性表示了很多关注，但对化疗可能导致的中枢神经系统变化知之甚少。本提案旨在研究50名接受常用化疗方案用于辅助治疗的早期乳腺癌妇女。除了关注先前研究中确定的特定认知问题的认知测试外，该试验还将关注磁共振成像（MRI）定义的神经解剖学和神经功能变化，包括功能性MRI（fMRI）检查认知操作（如记忆任务）期间大脑活动的变化，以及提供大脑白色完整性精细成像的技术（扩散张量成像，DTI）。我们还将测试是否APOE基因型，这已与认知功能障碍的老化和痴呆症，可能与认知功能障碍的发展与化疗。患者将在化疗治疗前、化疗治疗后和一年时进行认知功能测试、成像和采血。从该项目中获得的信息将用于确定这种并发症的风险和频率，并导致进一步的大型试验，以探索干预措施。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chemotherapy-related cognitive dysfunction, so called "chemobrain" is a widely reported yet poorly defined complication of chemotherapy. Although much concern has been expressed about this potential toxicity, little is know about the central nervous system changes that may result from chemotherapy administration. This proposal is designed to study 50 women with early stage breast cancer receiving commonly used chemotherapy regimens used for adjuvant treatment. In addition to cognitive testing focusing on specific cognitive problems identified from prior studies, the trial will focus on neuroanatomical and neurofunctional changes defined by magnetic resonance imaging (MRI) including both functional MRI (fMRI) examining alterations in brain activity during cognitive operations such as memory tasks, and a technique that provides exquisite imaging of the white matter integrity of the brain (diffusion tensor imaging, DTI). We will also test whether the APOE genotype, which has been related to cognitive impairment in aging and dementia, may be associated with the development of cognitive dysfunction with chemotherapy. Patients will have cognitive function testing, imaging and blood collection prior to chemotherapy treatment, after chemotherapy treatment, and at one year. The information obtained from this project will be used to define the risk and frequency of this complication and lead to further larger trials that will explore interventions.